Your browser doesn't support javascript.
loading
Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface.
Toyoda, Yosuke; Morimoto, Kazushi; Suno, Ryoji; Horita, Shoichiro; Yamashita, Keitaro; Hirata, Kunio; Sekiguchi, Yusuke; Yasuda, Satoshi; Shiroishi, Mitsunori; Shimizu, Tomoko; Urushibata, Yuji; Kajiwara, Yuta; Inazumi, Tomoaki; Hotta, Yunhon; Asada, Hidetsugu; Nakane, Takanori; Shiimura, Yuki; Nakagita, Tomoya; Tsuge, Kyoshiro; Yoshida, Suguru; Kuribara, Tomoko; Hosoya, Takamitsu; Sugimoto, Yukihiko; Nomura, Norimichi; Sato, Miwa; Hirokawa, Takatsugu; Kinoshita, Masahiro; Murata, Takeshi; Takayama, Kiyoshi; Yamamoto, Masaki; Narumiya, Shuh; Iwata, So; Kobayashi, Takuya.
Afiliação
  • Toyoda Y; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Morimoto K; School of Medicine, Tsinghua University, Beijing, China.
  • Suno R; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Horita S; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Yamashita K; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Hirata K; RIKEN SPring-8 Center, Sayo-cho, Sayo-gun, Hyogo, Japan.
  • Sekiguchi Y; RIKEN SPring-8 Center, Sayo-cho, Sayo-gun, Hyogo, Japan.
  • Yasuda S; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Shiroishi M; Department of Chemistry, Graduate School of Science, Chiba University, Inage, Chiba, Japan.
  • Shimizu T; Institute of Advanced Energy, Kyoto University, Uji, Kyoto, Japan.
  • Urushibata Y; Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan.
  • Kajiwara Y; Japan Science and Technology Agency (JST), Platform for Drug Discovery, Informatics, and Structural Life Science, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Inazumi T; NB Health Laboratory Co. Ltd., Kita Ward Sapporo City, Hokkaido, Japan.
  • Hotta Y; NB Health Laboratory Co. Ltd., Kita Ward Sapporo City, Hokkaido, Japan.
  • Asada H; Graduate School of Energy Science, Kyoto University, Uji, Kyoto, Japan.
  • Nakane T; Molecular Profiling Research Center for Drug Discovery (MOLPROF), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.
  • Shiimura Y; Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Oe-Honmachi, Kumamoto, Japan.
  • Nakagita T; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Tsuge K; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Yoshida S; JST, the Strategic Basic Research Program, Membrane Protein Crystallography Project, Kyoto, Japan.
  • Kuribara T; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Hosoya T; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Sugimoto Y; JST, the Strategic Basic Research Program, Membrane Protein Crystallography Project, Kyoto, Japan.
  • Nomura N; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Sato M; Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Oe-Honmachi, Kumamoto, Japan.
  • Hirokawa T; Laboratory of Chemical Bioscience, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo, Japan.
  • Kinoshita M; Laboratory of Chemical Bioscience, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo, Japan.
  • Murata T; Japan Science and Technology Agency (JST), Platform for Drug Discovery, Informatics, and Structural Life Science, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Takayama K; Laboratory of Chemical Bioscience, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo, Japan.
  • Yamamoto M; Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Oe-Honmachi, Kumamoto, Japan.
  • Narumiya S; Japan Agency for Medical Research and Development (AMED), Core Research for Evolutional Science and Technology (CREST), Chiyoda-ku, Tokyo, Japan.
  • Iwata S; Department of Medical Chemistry and Cell Biology, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto, Japan.
  • Kobayashi T; JST, the Strategic Basic Research Program, Membrane Protein Crystallography Project, Kyoto, Japan.
Nat Chem Biol ; 15(1): 18-26, 2019 01.
Article em En | MEDLINE | ID: mdl-30510193
ABSTRACT
Prostaglandin E receptor EP4, a G-protein-coupled receptor, is involved in disorders such as cancer and autoimmune disease. Here, we report the crystal structure of human EP4 in complex with its antagonist ONO-AE3-208 and an inhibitory antibody at 3.2 Å resolution. The structure reveals that the extracellular surface is occluded by the extracellular loops and that the antagonist lies at the interface with the lipid bilayer, proximal to the highly conserved Arg316 residue in the seventh transmembrane domain. Functional and docking studies demonstrate that the natural agonist PGE2 binds in a similar manner. This structural information also provides insight into the ligand entry pathway from the membrane bilayer to the EP4 binding pocket. Furthermore, the structure reveals that the antibody allosterically affects the ligand binding of EP4. These results should facilitate the design of new therapeutic drugs targeting both orthosteric and allosteric sites in this receptor family.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Prostaglandina E Subtipo EP4 Limite: Animals / Humans Idioma: En Revista: Nat Chem Biol Assunto da revista: BIOLOGIA / QUIMICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Prostaglandina E Subtipo EP4 Limite: Animals / Humans Idioma: En Revista: Nat Chem Biol Assunto da revista: BIOLOGIA / QUIMICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão